Pegylated Interferon plus Ribavirin Combination Therapy for Chronic Hepatitis C with High Viral Load of Serum Hepatitis C Virus RNA, Genotype 1b, Discontinued on Attaining Sustained Virological Response at Week 16 after Onset of Acute Pancreatitis

• Published in: Digestion Vol. 79; no. 1; pp. 36 - 39
• Main Authors: Kim, Soo Ryang, Imoto, Susumu, Mita, Keiji, Taniguchi, Miyuki, Sasase, Noriko, Muramatsu, Akira, Kudo, Masatoshi, Kitai, Satoshi, El-Shamy, Ahmed, Hotta, Hak, Hayashi, Yoshitake
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.01.2009
• Subjects: Acute Disease; Aged; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Case Report; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis C virus; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - genetics; Hepatitis C, Chronic - virology; Humans; Interferon-alpha - adverse effects; Interferon-alpha - therapeutic use; Liver Function Tests; Pancreatitis - chemically induced; Polyethylene Glycols - adverse effects; Polyethylene Glycols - therapeutic use; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin - adverse effects; Ribavirin - therapeutic use; RNA, Viral - blood; RNA, Viral - genetics; Viral Load; Sustained virological response; Early viral dynamics, genotype 1b; Acute pancreatitis; Chronic hepatitis C
• ISSN: 0012-2823; 1421-9867
• DOI: 10.1159/000203639

Recent clinical trials have shown that pegylated interferon-α (PEG-IFN-α) in combination with ribavirin (RBV) improves the rate of sustained virological response (SVR), with over 50% of patients demonstrating a positive response to treatment. However, no SVR has been reported when PEG-IFN/RBV combination therapy is discontinued by week 16, especially in cases of chronic hepatitis with a high viral load of serum hepatitis C virus (HCV) RNA, genotype 1b. Here, we describe SVR in a 67-year-old woman whose PEG-IFN/RBV combination therapy for chronic hepatitis C with a high viral load of serum HCV RNA, genotype 1b, was discontinued after 16 weeks because of the onset of PEG-IFN plus RBV-induced acute pancreatitis. Among viral factors, substitution of amino acid 70 (Arg) and 91 (Leu) in the core region and HCV RNA negativity were observed after 8 weeks. Host factors including low body weight, no alcohol consumption, no coinfection with hepatitis B virus, slight fibrosis, and viral factors including early viral clearance, double wild type in the core region, may have contributed to the SVR irrespective of the discontinuation of the combination therapy at week 16. Moreover, PEG-IFN plus RBV-induced acute pancreatitis might have been related to the SVR.